Drug intelligence / Profile preview

SBT-501

Development stage: Preclinical
Lead developer: Singh Biotechnology
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Parenteral

Overview

SBT-501 is a single-domain antibody (sdAb), also known as a nanobody, developed by Singh Biotechnology for the prophylaxis of SARS-CoV-2 infection. It is designed to prevent infection by the original strain of SARS-CoV-2 as well as its emerging variants. As a nanobody-based biologic, SBT-501 leverages Singh Biotechnology's proprietary platform to produce small, stable antibody fragments that can potentially neutralize viral particles. The candidate was highlighted in a 2021 Military Health System Research Symposium (MHSRS) abstract as a prophylactic drug for COVID-19. SBT-501 is part of a broader infectious disease program at Singh Biotechnology that includes SBT-500.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SBT-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBT-501.

Explore the full profile